This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

3 Top Funds' Best Stock Picks Crush S&P 500

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

T. Rowe Price Health Sciences Fund (PRHSX), a $3 billion fund with a portfolio of 158 stocks, is up 19% this year and 43.5% over the past 12 months. The diverse fund has only 27% of its assets in its top 10 holdings and the annual portfolio turnover is a slim 36%. The fund favors small- and mid-cap stocks.

Kris Jenner has been the manager since 2000.

Alexion Pharmaceuticals (ALXN), the top holding at 6.4% of the fund, is up 15% this year. The company focuses on the development and marketing of drugs for life-threatening medical conditions. Mutual funds own 59% of its shares.

Valeant Pharmaceuticals International (VRX), up 75% this year, makes up 3.6% of the fund. The Canadian company, composed of the former pharmaceutical firms Valeant Pharmaceuticals and Biovail International, licenses and develops specialty drugs in the neurology and dermatology category. It sells more than 100 branded products.

Gilead Sciences (GILD), 3% of the portfolio, is up 12.9% this year. The company develops and markets therapies to treat life-threatening infectious diseases.






The $1.2 billion Fidelity Select Biotechnology Fund (FBIOX) has a return of 18.6% this year and 37% over the past 12 months. The 95-stock fund has been managed by Rajiv Kaul since October 2005. The annual portfolio turnover is relatively high, at 119%, and 57% of its assets are concentrated in the top 10 positions.

Its top holding is the biotechnology giant Amgen (AMGN), which at 18.4% of the fund, is more than double the allocation of the next largest stock. Amgen has risen 9% this year. The company is a leader in biotechnology-based human therapeutics, with expertise in renal disease and cancer-care products.

Alexion Pharmaceutical (ALXN) is the second-largest holding, at 6.7% of fund's assets.

Vertex Pharmaceutical (VRTX), 6.5% of the fund, is up 58.6% this year. It is a developer of small-molecule drugs for the treatment of life-threatening diseases. It is close to commercializing telaprevir, a hepatitis-C treatment in late-stage development with the potential to achieve blockbuster status, according to Morningstar analysts.

The fourth-largest position is Biomarin Pharmaceutical (BMRN), at 4.5% of the fund. The company, which is building a portfolio of genetic disease therapeutics, many used in the treatment or rare diseases, is up 2% this year.

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

2 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,943.81 +28.74 0.17%
S&P 500 1,967.57 +2.89 0.15%
NASDAQ 4,415.49 +19.2860 0.44%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs